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ABSTRACT
Purpose To investigate, for the first time, the performance of a dry
powder inhaler (DPI, Aerolizer®) in the case of a model drug (i.e.
albuterol sulphate) formulated with spray dried mannitol carrier parti-
cles with homogeneous shape and solid–state form but different sizes.
Methods Spray dried mannitol (SDM) particles were charac-
terized in terms of size, surface area, morphology, water con-
tent, solid–state, density and electrostatic charge by a novel
approach. DPI formulations composed of SDM and albuterol
sulphate (AS) were prepared and evaluated in terms of drug
content homogeneity and in vitro aerosolization performance.
Results All SDM particles generated similar fine particle fractions
of AS. Formulations consisting of larger SDM particles demon-
strated better drug content homogeneity, reduced amounts of
drug loss and reduced oropharyngeal deposition. Comparing
different SDM products demonstrated that SDM powders with
relatively poorer flowability, wider size distributions and higher
charge density generated DPI formulations with poorer drug
content homogeneity and deposited higher amount of drug on
the inhaler, mouthpiece adaptor and throat. DPI formulation total
desirability increased linearly with the mean diameter of SDM.
Conclusion Particle shape and solid–state form of mannitol
could dominate over carrier size, bulk density, flowability and
charge in terms of determining the aerosolization behaviour of
AS formulated with mannitol carrier, at least within the experi-
mental protocols applied in the present study.
KEY WORDS aerosolization . albuterol sulphate . electrostatic
charge . physicochemical properties . spray driedmannitol
INTRODUCTION
Mannitol is an attractive carrier in DPI systems due to its
remarkable merits. These include for instance that mannitol
gives a high sweet aftertaste that could be used to monitor the
dose taken by the patient (1) and does not have a reducing
effect making it a potential carrier for the aerosol delivery of
proteins (2) and drug particles that contain a primary amine
group (e.g., budesonide and formoterol).
The influence of carrier physicochemical properties on
drug dispersion from dry powder inhalers is not completely
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understood. In the literature, controversial reports can be
found on the effect of these properties on drug aerosolisation
efficiency. For example, both high (3) and low (4) fine particle
fractions (FPF) of drug were documented by decreasing
particle size of carrier particles. It is believed that the degree
by which carrier particle size affects DPI formulation perfor-
mance is influenced by other factors such as surface rough-
ness (5), surface energy (6), type of drug (7), type of inhaler
(8), chemical nature of carrier (9) and amounts of fine addi-
tives (10). A direct proportional relationship was reported
between specific surface area of carrier particles and FPF of
drug (11), but the reverse trend was found too (12). Good
aerosolisation performance was observed when the bulk and
the tap densities of the carrier powder were low (13) or high
(14). Formulations with good (3) and poor (10) flow proper-
ties produced a high FPF of drug upon aerosolization. Both
negative (15) and positive (16) relationships were established
between carrier surface energy and FPF of drug. The FPF of
drug increased with the elongation ratio of carrier particles
employed within the formulation (17).
Indeed, studying the effect of one (independent) physico-
chemical property on DPI performance is challenging because
manipulating one property could alter the others. Therefore,
most studies focused on one property and gave less attention to
other properties that could have varied alongside the particular
property being studied. For example, in comparison to large
particles of the same material, particles with smaller size could
have smoother surfaces (18), have reduced relative degree of
crystallinity, have increased surface energy (19), show high water
uptake (20), and could generate powders with different charge
density (21), high cohesive forces and poor flow properties.
The apparent disagreement among different reports could
be partly attributed to the heterogeneous nature of carriers
inspected. Therefore, it was the aim of this study to systemati-
cally evaluate the influence of particle size of a promising
carrier, spray dried mannitol, on the performance of a DPI in
the case of ‘homogeneous’ spherical carrier particles having a
similar morphology, a similar true density and a similar solid–
state form. This research was performed with a view to increase
the knowledge of understanding the influence of carrier phys-
icochemical properties on the performance of DPIs.
MATERIALS AND METHODS
Materials
Spray dried mannitol (SDM, Mannogem EZ Spray Dried) was
sourced SPI pharma, UK. Micronized albuterol sulphate (AS,
d10%=0.5±0.0 μm, d50%=1.7±0.1 μm, d90%=3.1±0.3 μm
(22)) was purchased from LB Bohle, Germany. For comparison
purpose, α–mannitol (acetone crystallized mannitol, ACM, pre-
pared as described by Kaialy et al. (17)), β–mannitol (commercial
mannitol A, CM–A, Fisher Scientific, UK) and δ–mannitol
(commercial mannitol B, CM–B, Parteck® Delta M, Merck
KGaA, Darmstadt, Germany) were used for solid–state analyses.
Sieving
SDMpowder was sieved to collect mannitol particles in different
size fractions. Two different types of sieving were employed:
mechanical sieving (mechanical shaker, Endecotts Ltd, UK)
and air jet sieving (Copley Scientific, Nottingham,UK) operating
at a gas volume flow that generates a negative pressure of 4 Kpa
and rotating nozzle speed of 50 rpm.Mannitol bulk powder was
poured above the 125–μm sieve that has been placed on top of
different sieves (Retsch® Gmbh Test Sieve, Germany) with
smaller aperture sizes above one another as follows: 90–μm,
63–μm, 45–μm, 20–μm and a metal collection plate. The me-
chanical shaker was operated for 30min, after which the amount
of powder remained on top of each different sieve was further
subjected to air jet sieving for 15 min. Following the sieving
process, particles with different size fractions [90–125 μm
(SDM–A), 63–90 μm (SDM–B), 45–63 μm (SDM–C) and 20–
45 μm (SDM–D) were collected and kept in sealed glass vials
until used. All the analyses described below were performed on
the sieved samples.
Particle Size Measurements
Particle size analysis was conducted using a Sympatec
(Clausthal–Zellerfeld, Germany) laser diffraction–particle size
analyzer as described in detail elsewhere (23). Mean diameter
(MD, based on volume) and theoretical specific surface area
(based on volume, assuming an ideal spherical smooth surface
of the particles) were calculated by the Sympatic software.
Ten determinations were measured for each sample.
BET Analyses
BET surface area was measured by nitrogen adsorption
using Micromeritics Gemini 6 (Norcross, USA) automated
gas sorption system model. The determination of external
surface area was estimated by using the standard t–plot
calculations by using experimental points at a relative pres-
sure of P/P0=0.1–0.5. All measurements were done in
triplicate. Surface roughness of SDM particles was estimated
according to equation 1 (Eq. 1).
Roughness ¼ BET specific surface area=theoretical
volume specific surface area
ð1Þ
Image Analysis Optical Light Microscopy
Quantitative particle size and shape analysis were conducted
using a computerized morphometric image analysis system
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(Leica DMLA Microscope; Leica Microsystems Wetzlar
GmbH, Wetzlar, Germany; Leica Q Win Standard
Analysing Software) (24). Particle size and geometric
shape were quantified using several parameters includ-
ing equivalent diameter (Dequi), aspect ratio, convexity
ratio, surface factor and sphericity (25). Dmax and Dmin
were defined as the maximum and the minimum diameter of
particle respectively.
Scanning Electron Microscopy/Energy Dispersive
X–ray Analyses
The use of only shape factors might not necessarily be
sufficient to characterize particle shape. Therefore, all
SDM particles were further quantitatively and qualitatively
analyzed by scanning electron microscope (SEM). The pow-
der samples were sputtered with chromium under argon
vacuum using the sputter coater (Edwards S 150B Sputter
Coater, 15 nm layer thickness). Electron micrographs with
different magnifications of SDM samples were obtained
using a SEM (HITACHI SU 8030, Japan) operating at
1–2 kV. The specimens were mounted on a metal stub with
double–sided adhesive tape. Additionally, SEM images for
AS powder and SDM:AS formulation blends were taken at
different magnifications. Elemental composition energy dis-
persive X–ray (EDX) chemical imaging analysis were carried
out on albuterol sulphate–spray dried mannitol formulation
samples using a Thermo–Noran system 7 detection system
on the HITACHI SU 8030 FEG–SEM. A working distance
of 8 mm, an accelerating voltage of 5 kV and a livetime of
100 s were used. Before analyses, samples were carbon
coated to remove surface charging. Carbon coating was
performed in the Polaron Emitech SC7640 Sputter Coater
in a low–pressure atmosphere and a current of 100 A for 30s.
Carbon coating was used because it does not disturb the
X–ray signals emitted from the sample and gives better
signal strength.
Water Content Analyses
Themoisture content of the SDM samples was determined semi–
automatically by the Karl Fisher method (Metter Toledo, C20
Coulometric KF Titrator, Switzerland). The Fischer reagent solu-
tion was Hydranal® Coulomat AF (Sigma Aldrich, USA). The
titration of each sample was repeated three times and an average
value was taken.
Differential Scanning Calorimetry
A differential scanning calorimeter (DSC822e, Mettler
Toledo, Switzerland) was conducted as descried previous-
ly (14) to characterize the solid–state nature of different
SDM samples. Each sample was heated from 25°C to
300°C at a heating rate of 30 K/min (Such heating rate
was shown previously to be preferable in terms of iden-
tification of δ–mannitol from α– and β–mannitol (14)). In
order to detect the presence of possible amorphous
mannitol, all mannitol samples were analyzed by DSC
from −20°C to 250°C at a heating rate of 10 K/min.
The melting enthalpies of all samples were calculated in
triplicate by Mettler software.
Fourier Transform Infrared Spectroscopy
A SPECTRUM–ONE Fourier transform infrared (FT–IR)
spectrometer (PerkinElmer, Massachusetts, USA) was used
as descried previously (14) to analyse all SDM samples. A
scanning range of 450–4,000 cm−1 with a 1 cm−1 resolution
was used.
Powder X–ray Diffraction
The powder X–ray diffraction (PXRD) patterns of all SDM
samples were collected on a Siemens DIFFRACplus 5,000
powder diffractometer with Cu Kα radiation (1.54056 Å)
according to the experimental procedure explained else-
where (26). Quantitative mannitol crystal form analysis
(% α–, % β–, or % δ–mannitol) were performed by
Rietveld refinement using Topas v4 (Bruker) (26). The re-
producibility of the PXRD patterns was verified by collecting
multiple patterns of four different specimens of each sample.
To obtain an accurate and quantitative phase analyses of
different mannitol samples, all PXRD patterns were ana-
lyzed by the Rietveld refinement technique using TOPAS–
Academic V4 software. Lorentzian component convolutions
of diffraction peaks varying in the diffraction angle 2θ as a
function of 1/cos θ. Implemented into a whole pattern fit of
the program TOPAS Academic V4, the approach yields
domain sizes (crystallite sizes).
Particle True Density Measurements
True density of all SDM samples (particle mass/particle volume
apart from both open and closed pores) was determined using an
ultrapycnometer 1,000 (Quantachrom, USA) under helium gas
(22). The mean of six determinations was recorded for each
sample.
Characterization of Bulk and Flow Properties of Spray
Dried Mannitol Powders
Bulk density (or apparent density), tap density (or drop
density) and porosity (Eq. 2) of each mannitol powder sample
were measured as important descriptors of powder bulk
cohesive properties. Carr’s index (CI, Eq. 3) was measured
for all samples as an indication of powder flowability. The
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method incorporated was described elsewhere (27). Each
sample was analysed five times.
Porosity ¼ 1− Bulk density
True density
 
 100 ð2Þ
CI ¼ Tap density − Bulk density
Tap density
 
 100 ð3Þ
Evaluation of Electrostatic Properties of Spray Dried
Mannitol Powders
A tribo–electric device electrostatic inductive sensor was
used to investigate the tribo–electrification of SDM and AS
bulk powders (28). Such novel method allows the detection
and measurement of charge distribution on the charge sign
basis in a population of particles. A sample of each powder
was fed in the cylindrical sensor with the help of vibratory
feeder and conveyed toward the sensor by gravity in a
vertical direction. Special care was taken by considering the
adhesion property of particles with the wall of the sensor.
After each experiment, the inner tube was replaced in order
to remove any deposits, impurities or surface charge that
may have been present on the surface from a previous test. A
fresh sample was used for each test experiment. Each sample
was analyzed six times (humidity and temperature controlled
laboratory: 50% RH, 22°C). The positive charge is the sum
of positive charges whereas the negative charge is the sum of
negative charges. The net charge is the sum of positive
charges and negative charges, whereas the overall absolute
charge is the sum of absolute charges detected regardless of
sign of charge. The charge–to–mass ratio (CMR or charge
density) was defined as the charge (negative charge for N–
CMR, positive charge for P–CMR, net charge for net–
CMR, or overall absolute charge for absolute–CMR) per
unit mass, in nC/g.
Preparation of AS–Mannitol Formulations
Each mannitol powder (5 g) was blended with AS powder
(67.5: 1, w/w, Ventolin Rotacaps®). This blending was
performed in a cylindrical aluminium container (6.5×8 cm)
using a Turbula® mixer (Maschinenfabrik, Basel, Switzerland)
at a constant speed of 100 rpm for 30 min for the preparation
of all formulations under similar protocol. Once prepared, all
formulations were stored in tightly sealed glass vials for 7 days
prior to any investigation until used.
Quantification of Albuterol Sulphate
Albuterol sulphate (AS) content was analysed using HPLC
(Waters, USA). A mixture of methanol and 0.25% (w/v)
1–heptane sulfonic acid sodium salt (45/55, v/v) was
used as mobile phase. The flow rate of the mobile
phase was 2 mL/min and the assay wavelength was
200 nm. The method incorporated was described in
detail elsewhere (27).
Drug Homogeneity Assessment
After blending, ten randomly selected samples (33±1.5 mg,
equivalent to a unit dose of AS: 481±22 μg) were taken from
different spots of each formulation powder for assay of AS
content. Each sample was dissolved in 100 mL distilled water
in a volumetric flask. For each formulation, % potency was
calculated as the percent amount of AS to the nominal dose.
Per cent coefficient of variation (% CV) was calculated to
determine the degree of AS content homogeneity.
In Vitro Aerosolisation Study
After blending, each formulation was filled manually into
hard gelatin capsules (size 3) with 33±1.5 mg powder.
Before any investigation, all filled capsules were stored in
sealed glass vials for at least 24 h in order to allow any
charge–relaxation to occur. Pharmacopoeial deposition pro-
files of all formulations were assessed in vitro (22°C, 50% RH)
using Aerolizer® inhaler device (Novartis, Switzerland) and a
Multi–Stage Liquid Impinger (MSLI) equipped with a USP
induction port (IP) (Copley Scientific, Nottingham, UK) at a
flow rate that corresponds to a pressure drop of 4kPa across
the device (92 L/min), as adopted from Kaialy et al. (23).
Amounts of AS deposited on the inhaler with mouthpiece
adaptor (I+M), induction port (IP, throat) and all stages
of the MSLI were quantified. Ten capsules (ten doses)
were actuated separately for each formulation tested, and
the aerosolization test for each formulation was repeated
four times (40 capsules in total). Several parameters were
employed to quantify AS deposition profiles from each
formulation including fine particle fraction (FPF≤5μm), im-
paction loss (IL), dispersibility (DS), effective inhalation
index (EI), mass median aerodynamic diameter (MMAD)
and geometric standard deviation (GSD), as defined and
explained previously (29).
Overall Desirability
Desirability function (DF) value is helpful in terms of evalu-
ating several parameters concurrently and hence could be
functional for experimental design–based optimization. To
perform a quantitative comparison of different DPI formu-
lations containing different SDM particles, a desirability
function (di, Eq. 4) was defined (22):
di ¼ Y i−Y minY max−Y min ð4Þ
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where Yi, Ymax and Ymin are the actual observed, the maxi-
mum acceptable and the minimum acceptable values for the
response variable respectively. Typically, optimum DPI for-
mulation is required to demonstrate a good drug content
homogeneity (low % CV, important to attain uniform
metering doses by the patient), good flow properties (low %
CI, essential to achieve good dose homogeneity, dose
metering and industrial processing), minimal drug loss (low
% I+M), minimal deposition on throat (low % IP) and
maximal deposition on lower airways (high % FPF, which
could be, theoretically, directly related to biological effec-
tiveness). Therefore, FPF, CV, CI and I+M+IP (% deposi-
tion on I+M+IP) indexes were selected as key parameters in
comparative evaluation of different DPI formulations using
overall desirability function (DF) as follows (Eq. 5, see
Supplementary Material 1 for minimum and maximum
response variables):
DF ¼ dFPF þ 1dCV þ
1
dCI
þ 1
dIþMþIP
 1
4
ð5Þ
RESULTS AND DISCUSSION
Particle Size Distribution for Spray Dried Mannitol
SDM particles demonstrated considerably different particle size
distributions (PSDs) as indicated by laser diffraction (volume–
weight) (Fig. 1a, Supplementary Material 2) and further quali-
tatively and quantitatively (number–weight) ascertained by
SEM (Fig. 2, Supplementary Material 3). All SDM particles
exhibited symmetric, lognormal, mono–modal size distributions
(Supplementary Material 2). Particle sizes at 10% (d10%), 50%
(d50%, median diameter) and 90% (d90%) volume distribution
(Fig. 1a) and particle surface roughness (Fig. 1b) for different
SDM samples were in the following rank order: SDM–A >
SDM–B> SDM–C > SDM–D. On the other hand, the follow-
ing rank order can be formulated for SDM particles in terms of
both span (Fig. 1a) and BET surface area (Fig. 1b): SDM–A
< SDM–B ≈ SDM–C < SDM–D. In general, a higher particle
surface area could be related to smaller mean size, broader
particle size distribution, higher surface energy (12) and/or
higher specific charge (30).
Fig. 1 Particle size at 10% (black diamond suit, d10%), 50% (black square, d50%, median diameter), 90% (black up-pointning triangle, d90%) volume
distribution and span (a); BETsurface area and roughness (black circle) (b) for spray dried mannitol (SDM) particles with different size fractions: 90–125 μm
(SDM–A), 63–90 μm (SDM–B), 45–63 μm (SDM–C) and 20–45 μm (SDM–D); mean diameter for different SDM particles (mean±SD, n=10) in relation
to BETsurface area (lozenge), span (white square) (c) and roughness of SDM particles (d). Smaller SDM particles have a higher specific surface area, a smoother
surfaces, and generated relatively less–homogeneous powders.
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Mostly, particle size of SDM samples fell into the nominal
sieve size range, which could be due to uniform spherical shape
of SDM particles (Figs. 1a and 2, Supplementary Material 2
and 3). Span value for all SDM powders ranged between
0.6±0.1 and 0.8±0.0 (Fig. 1a) indicating homogeneous size
distributions (span <1). Such homogeneous size distribution is
advantageous in terms of quality and effectiveness of the DPI
formulation because high polydispersity of aerosol particle size
might lead to high variations in lung deposition regions. Fine
mannitol particles (≤5 μm) were less than 1% (v/v) for all SDM
samples (SupplementaryMaterial 2), indicating that the applied
sieving process was efficient to eliminate almost all fine particles.
This is important in terms of direct comparison between differ-
ent spherical SDM particles since fine carrier particles could
considerably affect DPI performance (10).
Spherical SDM particles with smaller mean diameter
(MD) demonstrated higher BET specific surface area (linear,
r2=0.9466) (Fig. 1c), smoother surfaces (Fig. 1d) and gen-
erated powders with relatively less homogeneous size distri-
butions (higher span values, linear r2=0.9425) (Fig. 1c).
Particle Shape Analysis for Spray Dried Mannitol
Particle size data provided by image analysis were in agreement
with data provided by laser diffraction, since a direct linear
relationship (r2=0.9975) was established between particle
equivalent diameter (Dequi, obtained by image analyses) and
mean diameter (MD, obtained by laser diffraction) (Fig. 2a).
Statistically, all SDM particles demonstrated a similar
(P>0.05) aspect ratio (1.3±0.2), a similar Dmax/Dmin
(1.2±0.1), a similar convexity ratio (0.9±0.1), a similar surface
factor (0.9±0.2) and a similar sphericity (0.9±0.0) (mean±SD,
average of all samples) (Fig. 2b). This indicated that all SDM
particles have a similar shape, which was further confirmed by
Fig. 2 Relationship between equivalent diameter (Dequi, mean±SE, n≥1,000) obtained by image analyses optical microscopy and mean diameter (mean
±SD, n=10) obtained by laser diffraction (a); aspect ratio, Dmax/Dmin, convexity ratio, surface factor and sphericity (b); optical microscope photographs (c);
and scanning electron photographs (d) for spray dried mannitol (SDM) particles with different size fractions: 90–125 μm (SDM–A), 63–90 μm (SDM–B), 45–
63 μm (SDM–C) and 20–45 μm (SDM–D). SDM particles demonstrated a similar morphology.
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the representative photographs of different SDM particles
(Fig. 2c and d). All particle shape descriptors were around
unity with a relatively small standard deviation (≤ 0.2) indicat-
ing that all SDM particles were spherical–regular (uniform)–
shaped (Fig. 2b, c and d). Such similarity in terms of shape
among different carrier particles is of importance in terms of
straight evaluation between SDM particles because DPI per-
formance is dependent on the particle shape of carrier (4,17).
In addition, shape–similarity and low degree of agglomeration
could account for the agreement between image analysis and
laser diffraction in terms of particle size determination of SDM
particles (Fig. 2a–c). This is because both measurements
obtained by laser diffraction and image analysis are more
precise in the case of spherical particles.
Water Content Analysis for Spray Dried Mannitol
All SDM particles demonstrated a similar (negligible) amount
of water content (0.1±0.1%, w/w). This indicates the absence
of mannitol hydrate form all SDM particles. Additionally, this
indicates that, despite their relatively high surface area
(Fig. 1b), smaller SDM particles did not show higher moisture
content in comparison to larger particles. This could be at-
tributed to the non–hygroscopic behaviour of mannitol (31),
which is advantageous in terms of better physical and chem-
ical stability of the DPI formulation, lower degree of solid
bridging (by capillary forces which could cause irreversible
powder aggregation) and better DPI formulation aerosoliza-
tion (32). This suggests that SDM could be preferred in dry
powder inhalation formulations compared to other sugars that
have a hygroscopic nature such as xylitol and glucose.
Solid–State Characterization of Spray Dried Mannitol
Particles
All DSC traces showed one endothermic transition at
169.9±0.1–171.3±1.6°C (mean±SD, P>0.05) with similar
melting enthalpy (283.2±3.6–292.5±4.2 J/g, mean±SD,
P>0.05) (Fig. 3a). Such DSC curves suggest the presence of
α–mannitol and/or β–mannitol crystal form. There was no
detectable δ–mannitol (which would have produced a melting
endotherm at 150–158°C) (14) or free water (or surface water,
which would have produced an endothermic transition at
around 100°C) in the SDM samples. The absence of free water
was also confirmed by Karl Fischer analysis. Additionally, the
absence of any glass transition event around 13°C from the
DSC traces (Supplementary Material 4) confirms that there
was no detectable amount of amorphous mannitol within all
mannitol samples. Similar melting enthalpy (Fig. 3a) suggests a
similar relative degree of crystallinity for different SDM parti-
cles. In addition, SDM samples demonstrated similar melting
enthalpy to the mannitol control samples (ACM, CM–A and
CM–B) (253.3 ± 5.1–254.8 ± 3.9 versus 251.0 ± 2.4–
253.2±4.1 J/g). This suggested that SDM particles have a
similar degree of crystalline nature to the control mannitol
samples (Supplementary Material 4).
Mannitol exists in three common polymorphic forms, i.e.,
α–, β– and δ–. Since pure α– and β–mannitol are indistinguish-
able by DSC (23), all SDM particles were further analysed by
FT–IR (Fig. 3b) and PXRD (Fig. 4). All samples exhibited
similar FT–IR spectra indicating their similar molecular struc-
ture (Fig. 3b). The presence of sharp, characteristic diffraction
angles with no halo, background or peak widening in the
PXRD patterns of all samples confirms the crystalline nature
of all SDM samples (Fig. 4). All SDM particles exhibited α–
mannitol specific FT–IR band at 1,194 cm−1, β–mannitol
Fig. 3 Differential scanning calorimeter (DSC) traces heated from 25°C to
300°C at a heating rate of 30 K/min (a); and fourier transform infrared (FT–
IR) spectra (from 650 cm−1 to 1,600 cm−1) (b) for spray dried mannitol
(SDM) particles with different size fractions: 90–125 μm (SDM–A), 63–
90 μm (SDM–B), 45–63 μm (SDM–C) and 20–45 μm (SDM–D) (%T:
percent transmittance).
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specific FT–IR bands at 959 cm−1 and 929 cm−1 (Fig. 3b), α–
mannitol PXRD specific peaks at 2θ of 9.57, 13.79 and 17.2
and β–mannitol PXRD specific peaks at 2θ of 10.56, 14.71,
23.4 and 29.5 (Fig. 4). This indicates that all SDM samples
consist of mixtures of α–mannitol (58±2%) and β–mannitol
(42±2%) with no significant (P>0.05) difference between all
samples (Fig. 4). The specific FT–IR band of δ–mannitol (at
967 cm−1) and the PXRD diagnostic angle of δ–mannitol (at
9.7° and 22.2°) were absent from FT–IR spectra (Fig. 3b) and
PXRD patterns (Fig. 4) of all SDM samples, which agrees with
the DSC results (Fig. 3a). Structural PXRD data analyses
showed that ACM (α–mannitol), CM–A (β–mannitol) and
CM–B (δ–mannitol) have volume–weighted mean crystallite
sizes (LVol–IB) between 466 and 652 nm (Supplementary
Material 5). SDMparticles demonstrated amean crystallite size
between 517 and 930 nm (Supplementary Material 5). Such
values confirm the practically absolute crystalline nature
of all mannitol samples, which agrees with DSC results
(Supplementary Material 4). Indeed, it is well established in
the literature that spray driedmannitol could have a crystalline
solid–state which is one of the advantages of using mannitol
over lactose in DPI systems (33).
In conclusion, SDM particles with different size distributions
demonstrated similar polymorphic form (α–+β–mannitol
mixture), allowing the comparison of the influence of particle
size of uniform spherical SDM particles on the DPI perfor-
mance (6).
Characterization of Density, Porosity and Flowability
for Spray Dried Mannitol Powders
All SDM particles demonstrated similar true density
(1.42±0.02 – 1.45±0.02 g/cm3, P>0.05) (Supplementary
Material 6). This is beneficial for comparison between differ-
ent mannitol particles because carrier particles with a low–
density would have lower settling velocity, smaller aerody-
namic diameter in comparison with their geometric diameter
and a lower probability of impaction (due to lower inertial
forces generated during aerosolization) (34).
SDM samples demonstrated considerably different bulk
densities (from 0.42±0.01 to 0.49±0.01 g/cm3) and different
tap densities (from 0.48±0.01 to 0.58±0.02 g/cm3), both were
in the following rank order: SDM–A < SDM–B ≤ SDM–C <
SDM–D (Supplementary Material 6). CI for different SDM
powders was within the following rank order: SDM–A <
SDM–B < SDM–C < SDM–D (Supplementary Material 6)
ranging from 12.8±1.1% for SDM–A (good flow character) to
21.8±1.1% for SDM–D (fair or reasonable flow character).
Fig. 4 PXRD patterns and %
solid–state polymorphic form
(mean±SD, n=4) for spray dried
mannitol (SDM) particles with
different size fractions: 90–125 μm
(SDM–A), 63–90 μm (SDM–B),
45–63 μm (SDM–C) and 20–
45 μm (SDM–D). SDM particles
demonstrated a similar solid–state
form (mixture of α– and β–
mannitol).
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Porosity for different SDM powders was in the following order:
SDM–A > SDM–B > SDM–C > SDM–D (Supplementary
Material 6) ranging from 65.5 to 70.8%. The results showed
that the smaller themean diameter of SDMparticles the higher
the bulk density (linear, r2=0.9652), the higher the tap density
(linear, r2=0.9997) (Fig. 5a), the poorer the flowability (higher
CI) and the smaller the porosity (linear, r2=0.9206) (Fig. 5b) of
SDM powder. This could be explained as the arrangement
between small particles is more difficult than large particles.
Unlike bulk density and tap density, which are powder
descriptors, true density is a particle feature. The results indi-
cate that particle size had a negligible effect on the true density
of SDM particles, which could be related to their similar solid–
state form (Figs. 3 and 4). However, smaller SDM particles are
more cohesive which could be due to the higher interparticulate
average contact points between smaller particles.
Electrostatic Charge of Spray Dried Mannitol
and Albuterol Sulphate Powders
The charge properties of SDM and AS powders (Fig. 6) were
analysed using a recent novel approach developed in our
laboratory (28). Each peak of the signals represents a charged
particle travelling through the sensor. The directionality of
each peak determines the charging sign whereas the height of
the peak determines the level (magnitude) of charge (28). SDM
particles with smaller size (20–45 μm and 45–63 μm) carried
almost only electropositive charge behaviour (Fig. 6). Larger
SDMparticles (63–90 μmand 90–125 μm) exhibited a bipolar
charge trend. More particles were electropositively charged in
the case of 63–90 μm particles whereas more particles were
Fig. 5 Bulk density (white circle), tap density (black circle) (mean±SD, n=5) (a);
Carr’s index (CI) (increment) and porosity (black up-pointing triangle) (mean±SD,
n=5) (b) in relation to mean diameter (mean±SD, n=10) of spray dried
mannitol (SDM) particles with different size fractions: 90–125 μm (SDM–A),
63–90 μm (SDM–B), 45–63 μm (SDM–C) and 20–45 μm (SDM–D). Bulk
density and tap density increased with decreasing particle size of SDM.
Fig. 6 Particle charge pattern
(Hussain et al. (28)) for albuterol
sulphate (all particles are
electronegative) and spray dried
mannitol (SDM) particles with
different size fractions: 90–125 μm
(SDM–A, particles are
electropositive and
electronegative), 63–90 μm
(SDM–B, particles are
electropositive and
electronegative), 45–63 μm
(SDM–C, all particles are
electropositive) and 20–45 μm
(SDM–D, all particles are
electropositive).
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electronegatively charged in the case of 90–125 μm sieved
(Fig. 6). Unlike SDM powder, only strong electronegative
charge behaviour was observed for AS powder (Fig. 6).
The quantitative charging trends of different SDM parti-
cles are shown in Fig. 7a (negative charge–to–mass ratio,
N–CMR) and Fig. 7b (positive charge–to–mass ratio, P–CMR).
Bipolar charging was present in the case of SDM–A and
SDM–B powders, whereas for SDM–C and SDM–D almost
only an electropositive charge was detected (Figs. 7–a, –b).
The smaller the size of the spherical SDMparticles the smaller
was the negative charge density (Fig. 7a) and the higher was
the positive charge density (Fig. 7b). Indeed, the relationship
Fig. 7 Negative charge–to–mass ratio (N–CMR) (a), positive charge–to–mass ratio (P–CMR) (b), net charge–to–mass ratio (Net–CMR), absolute charge–
to–mass ratio (absolute–CMR) (nano coulomb/gram: nC/g, mean±SD, n=6) (c) for spray dried mannitol (SDM) particles with different size fractions: 90–
125 μm (SDM–A), 63–90 μm (SDM–B), 45–63 μm (SDM–C) and 20–45 μm (SDM–D); Net–CMR (mean±SD, n=6) in relation to mean diameter (black
circle) (mean±SD, n=10) and BET specific surface area ( ) (mean±D, n=3) of different SDM particles (d); P–CMR, N–CMR, net–CMR and absolute–
CMR for spray dried mannitol (20–125 μm, mean±SE, n=24 average of all samples) and albuterol sulphate (<5 μm, mean±SE, n≥6) (e). Charge density
of SDM is higher for SDM particles with smaller size and higher surface area. Albuterol sulphate drug has a different charge sign and a higher charge density
than spray dried mannitol carrier.
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between particle size and charge sign is a complex phenome-
non because it is dependent on both material chemical struc-
ture and the nature of contact surfaces (35). Nevertheless,
spherical mannitol particles with smaller size demonstrated
higher net charge density and higher absolute charge density
(Fig. 7c). This could be attributed to the relatively higher
surface area/mass ratio (Fig. 1b), higher particle–wall contacts
and greater particle number density in the case of smaller
particles. Fig. 7d shows that the net charge density of mannitol
powders increases with decreasing mean particle size and
increasing surface area of the spherical mannitol particles.
In comparison to SDM, regardless of the size of SDM parti-
cles, albuterol sulphate (AS) particles demonstrated a negligible
positive charge density, a significantly higher negative charge
density, a higher net charge density with opposite sign of charge
and a higher absolute charge density (Fig. 7e). This could be
attributed to the relatively large size (20–125 μm) and spherical
morphology (Fig. 2) for SMD particles in comparison to AS
particles (<5 μm). Generally, spherical particles are expected to
have less total charge than the angular (irregular) particles (e.g.,
AS, as shown later) since electrical charges are likely to distribute
homogeneously on spherical particles. Also, mechanically
micronized particles, such as albuterol sulphate, are usually
prepared by collision between coarse particles which could gen-
erate a high electrical charge.
Individual charged drug particles could induce an opposite
image charges in the upper airway regions accelerating drug
deposition in this region. In addition, drug–carrier adhesion
forces could be high in the case of drug particles and carrier
particles with opposite charges (36), such as albuterol sulphate
and mannitol investigated in this study (Fig. 7e). This could
be disadvantageous because it is expected to discourage
AS–mannitol detachment during aerosolization.
DPI Formulation Assessments
Drug Content Homogeneity
All formulations achieved uniform drug content with CV of
less than 6% (2.0 – 5.4%, Fig. 8a). This suggests that the
overall procedures of sampling, dissolving and drug analysis
were practically accurate and reproducible with satisfactory
mixing. Acceptable drug content homogeneity could be at-
tributed to the homogeneous size distributions (Fig. 1a),
Fig. 8 Potency (%, nominal dose, mean±SD, n=10) and coefficient of variation (% CV, ) of albuterol sulphate (AS) obtained from formulations containing
AS blended separately with spray dried mannitol (SDM) particles with different size fractions: 90–125 μm (SDM–A), 63–90 μm (SDM–B), 45–63 μm (SDM–
C) and 20–45 μm (SDM–D) (a); potency (black circle) and% CV (white square) of AS in relation to mean diameter (mean±SD, n=10) of SDM (b);% CVof
AS relative to Carr’s index (% CI, black up-pointing triangle) (mean±SD, n=5), span ( ) (mean±SD, n=10) (c) and charge density (white square, mean
±SD, n=6) (d) for SDM. Homogeneity of AS drug within AS–SDM interactive mixtures is reduced in the case of SDM particles with smaller size, poorer
flowability, wider size distributions and higher charge density.
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spherical shape (Fig. 2) and good–reasonable flowability
(Fig. 5b, Supplementary Material 6) of all SDM particles,
which could induce good drug–carrier distribution during
formulation blending process. Additionally, the opposite signs
of charge observed for SDM (mostly electropositive) and AS
(mostly electronegative, Fig. 7e) could increase powder cohe-
sion (and reduce powder segregation), potentially improving
the physical stability of the DPI blends (37).
The following rank order can be formulated for SDM:AS
formulations in terms of % potency and % CV of AS
according to SDM product: SDM–A < SDM–B < SDM–C
< SDM–D (Fig. 8a). Plotting mean diameter of SDM against
% potency (r2=0.9701) and % CV (r2=0.9229) (Fig. 8b),
indicating that the larger are the SDM particles the better is
the drug content homogeneity. This could be attributed to the
relatively more homogeneous size distribution (smaller span,
Fig. 1c) and better flow properties (smaller CI, Fig.5b) of large
SDM particles in comparison to smaller particles. Indeed,
linear relationships were established when plotting Carr’s
index (r2=0.9712), span (r2=0.8499) (Fig. 8c) and net charge
density (r2=0.9592) (Fig. 8d) of mannitol powder against %
CV of AS. Such relationships indicated that the variation in
drug content within the DPI formulation decreased with
improving the flowability, improving the size homogeneity
and/or reducing the charge density of SDM carrier powder.
Such findings could be explained as follow. The relatively
lower flowability for smaller SDM particles in comparison to
larger particles could lead to poorer drug–carrier distribution
during the blending process, whereas higher PSD polydisper-
sity could enhance the creation of relatively more drug–rich
areas within the formulation blends due to induced percolation
segregation (isolation by size). Additionally, higher electrostatic
charge density for smaller SDM particles in comparison to
larger particles (Fig. 7c) could promote the formation of
regions within the powder with different bulk properties pro-
moting relatively less dose homogeneity (5). Moreover, large
mannitol particles proved to have lower surface energy than
smaller particles (38) potentially leading to improved drug
content homogeneity because surface energy could represent
an energetic barrier to drug–carrier blending (39).
Higher potency for formulations containing smaller SDM
particles (Fig. 8b) could be ascribed to their relatively higher
surface area (Fig. 1c), thus their ability to carry higher
amounts of drug particles on their surfaces which minimize
the drug ‘losses’ in the case of smaller SDM particles by
indulging of AS in fine SDM particles.
SEM/EDX Analysis for SDM:AS Formulations
AS exhibited rectangular–shaped particles with most parti-
cles smaller than 5 μm confirming their appropriateness for
pulmonary drug delivery (Fig. 9a). However, a high level of
Fig. 9 SEM photographs of micronized albuterol sulphate alone (a); and formulation blends consisting of albuterol sulphate blended separately with spray
dried mannitol (SDM) particles with different size fractions: 90–125 μm (SDM–A) (b), 63–90 μm (SDM–B) (c), 45–63 μm (SDM–C) (d) and 20–45 μm
(SDM–D) (e) and scanning electron microscopy/energy-dispersive X-ray spot analyses on albuterol sulphate-spray dried mannitol formulation mixture (f).
Circles refer to AS particles. Both ‘single’ AS particles and AS-AS agglomerates could be detected within AS–SDM interactive mixtures.
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agglomeration was evident for AS powder, which is an
intrinsic property for fine particles. Such agglomerated drug
particles are likely to deposit on the upper airways upon
aerosolization, thus AS powder was mixed with coarse
SDM particles (Fig. 9b–e, Supplementary Material 7).
EDX in conjunction with SEM was employed to identify
the presence of AS drug on the SDM carrier surface and to
differentiate between AS particles and possible fine SDM
particles (Fig. 9f, Supplementary Material 8). Formulations
were analysed for sulphur (S) element that is present as a
sulphate salt of the albuterol powder but not present in
mannitol (Fig. 9f). To focus on specific locations on the
particle observed, spot analysis was used (Fig. 9e).
Following blending with SDM particles, most AS particles
were visualized as ‘solo’ particles (Figs. 9b–e) confirming the
formation of ordered (Fig. 8a) interactive drug–carrier DPI
formulation mixtures. Each interactive unit consists of small
AS particles adhered to a large SDM particle as, mainly,
monolayer type of adhesion (Fig. 9b–e), which was further
supported by the chemical information provided by EDX
analysis (Supplementary Material 8). However, some AS–AS
agglomerates were present (Fig. 9a–e) as adhered to coarse
SDM particles. The dispersion of AS following aerosoliza-
tion is dependent on the mechanical strength of the AS–AS
self–agglomerates.
Generally, a uniform distribution of elongated AS parti-
cles was observed on the spherical SDM particles suggesting
a good AS content homogeneity throughout the formula-
tions (Fig. 9b–e), which was in agreement with the homoge-
neity assessment of different formulations (Fig. 8a). More AS
particles were adhered on ‘rougher’ regions of the SDM
surfaces, whereas smooth regions had relatively fewer AS
particles (Fig. 9b–e). AS particles located within cavities on
SDM surfaces could be shielded by the mannitol surface
asperities from the detachment forces generated by the
turbulent airstream, thus might become entrapped and
motionless during aerosolization.
In Vitro Aerosolization Performance
The amounts of drug deposited onMSLI stages 1, 2, 3, 4 and
filter were not significantly influenced (P>0.05) by the SDM
particles with different sizes (Fig. 10a). This was also confirmed
by the similar (P>0.05) aerodynamic particle size distribution
of AS, FPF (21.4±2.7 – 25.7±3.3%), IL (59.4±3.9 –
64.5±6.2%), DS (23.9±2.8 – 28.6±3.6%), EI (43.8±2.3 –
48.1±3.2%), MMAD (2.7±0.2 – 2.9±0.2 μm) and GSD
(2.1±0.1 – 2.2±0.1) generated by all formulations (Fig. 10a).
Such data indicate that SDM powders with different sizes are
expected to deliver the same proportion of the dose to the
different regions of the airways.
Similar MMAD (Fig. 10b) suggested a similar AS–AS
degree of agglomeration within all formulations (Fig. 9b–e).
Experimental aerodynamic diameter of AS (MMAD,
assessed by MSLI) (Fig. 10b) was larger than its geometric
diameter (d50%=1.7±0.1 μm, assessed by laser diffraction).
This could be attributed to the presence of some AS–AS
agglomerates with the formulations (Fig. 9b–e), which possi-
bly could not be separated during aerosolization.
Additionally, since AS particles demonstrated a relatively
high charge density (Fig. 7e), AS particles could self–coagu-
late during aerosolization forming some agglomerates within
the airstream (5). A GSD higher than 1.25 (Fig. 10b) con-
firmed that the aerosolized AS particles were broadly dis-
tributed in size.
Formulation blends with improved device emptying is con-
sidered advantageous in DPI systems (40). Amounts of AS
remained in the I+M or deposited on the throat (IP) varied
significantly (Fig. 11a). Correlations were established demon-
strating higher amounts of AS deposited on I+M or IP for
SDM powders with higher charge density (Fig. 11b) and
poorer flowability (higher CI) (Fig. 11c). This can be explained
as mannitol particles with higher electrostatic charge and
poorer flowability could generate more cohesive powders,
thus become harder to fluidize via the airflow (may not be
completely deagglomerated by the Aerolizer® device). Less
cohesive powders (with lower electrostatic charge and better
flowability) fluidize more equivalently by an erosion mecha-
nism (41). In addition, particles with higher charge density
could have higher probability to deposit on the inhaler device
surface by electrical precipitation (5).
SDM carriers demonstrated improved aerosolization perfor-
mance compared to both commercial mannitol (FPF=14.8±1.1%
(14)) and commercial lactose (FPF=19.7±1.9% (42)),
suggesting SDMs as promising carriers for use in DPI
systems. This could be attributed to the uniform spherical
and more regular shape for spray dried mannitol particles
in comparison to the micronized commercial mannitol (14)
and the micronized commercial lactose (42), which could
lead to reduced drug–carrier contact area and consequent-
ly better drug aerosolization performance. Unlike SDM,
other important physical properties change with particle
size in the case of commercial lactose such as true density,
degree of crystallinity and brittleness. For example, large
commercial lactose particles (>45 μm) have brittle proper-
ties and delivered lower amounts of drug to the lower stages
of the impactor, whereas smaller lactose particles (<45 μm)
have ductile properties and delivered higher amounts of
drug to the lower stages of the impactor.
Although DPI formulation performance in terms of drug
content homogeneity (following blending and before aero-
solization) was correlated with the charge density of mannitol
(Fig. 8d), the different charging behaviour for SDM powders
(Fig. 7) did not significantly influence the FPF of drug
(following aerosolization of AS from the Aerolizer® device)
(Fig. 10b). Because aerosolization is more energetic than
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blending, it can be assumed that the initial charges of SDM
powders before aerosolization are negligible in magnitude in
comparison to the charges generated during powder disper-
sion (35). Therefore, the original levels of charge of mannitol
powders were inadequate to influence the FPF of drug fol-
lowing aerosolization.
The DF obtained for different formulations was in the
following rank order according to SDM product: SDM–A >
SDM–B > SDM–C > SDM–D (Fig. 12). Interestingly, regres-
sion analysis indicated that the overall DPI formulation desir-
ability increase linearly with increasing the mean diameter of
SDM particles (Fig. 12). This suggests that in the case of carrier
particles with similar spherical morphology, solid–state and
true density properties, larger particles outperform smaller
particles within DPI formulations in terms of total desirability,
at least for the model drug (AS) and model inhaler device
(Aerolizer®) used in this study.
Practically, it is nearly impossible to calculate the actual
drug–carrier interaction quantitatively since many factors
are involved in this process. Despite all formulations demon-
strated equivalent in vitro aerosolization performance, more
efforts would be required to test the lung deposition profiles
in vivo and at a wider range of drugs, inhaler devices and flow
rates. Indeed, it can be expected that the effect of particle size
of carrier particles on DPI performance might be masked or
accentuated depending on the materials used during formu-
lating. For example, the relatively low cohesive properties of
albuterol sulphate might contribute to the negligible varia-
tions in the formulations containing different spray dried
mannitol particles.
Fig. 10 Amounts of albuterol sulphate drug (AS) (%, nominal dose) deposited on Multi–Stage Liquid Impinger (MSLI) stage 1 (MSLI–1), stage 2 (MSLI–2),
stage 3 (MSLI–3), stage 4 (MSLI–4) and Filter; and aerodynamic particle size distribution of AS obtained from formulations containing AS blended with spray
dried mannitol (SDM) particles with different size fractions: 90–125 μm (SDM–A), 63–90 μm (SDM–B), 45–63 μm (SDM–C) and 20–45 μm (SDM–D) (a);
fine particle fraction (FPF), impaction loss (IL), dispersibility (DS), effective inhalation index (EI), mass median aerodynamic diameter (MMAD, ) and
geometric standard deviation (GSD, ) obtained from formulations containing AS blended with SDM particles (mean±SD, n=4). ‘S’ indicates statistically
similar (P>0.05). SDM particles demonstrated similar aerosolization performance.
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CONCLUSION AND OUTLOOK
This study showed the effect of particle size of an attractive
carrier (i.e., mannitol) that has uniform physical properties in
terms of shape, solid–state form and true density on dry powder
aerosol performance. Larger mannitol particles were more
desirable than smaller particles due to the minimized dose
variability, better flowability, reduced oropharyngeal deposition
and lower charge density. Small mannitol particles produced
similar fine particle fraction of drug to large particles.
Particle size had no significant effect on particle shape,
true density and solid–state of spray dried mannitol particles.
However, the smaller the size of the spherical mannitol
particles the higher the particle surface area, the smoother
the particle surface texture, the higher are the powder bulk
and tap densities, the poorer the powder flowability and the
higher the powder electrostatic charge of mannitol, but all
the latter factors had a negligible influence on drug aerosol-
ization behaviour. This suggested that the morphology and
solid–state form of carrier particles could be determining
properties in predicting the DPI aerosolization performance
over carrier particle size and carrier powder bulk and charge
properties.
As particle size of spray dried mannitol decreased, spray
dried mannitol particles became more electro–positively
charged and less electro–negatively charged. Poorer or en-
hanced aerosolization behaviour was not a property inherent
to larger size of mannitol carrier particles. For example, in
the case of ‘uniform’ spherical carrier particles, size is be-
lieved to be a minor factor affecting DPI performance. We
believe that the controversial conclusions reported by differ-
ent studies could be due to the interdependence of physico-
chemical properties on one another. Therefore, a great
caution must be kept in mind when relating DPI perfor-
mance deposition parameters with a physical property of
carrier particles because it might not be the controlling factor
influencing it. This research is believed to have a significant
application in formulation design and processing strategies
for pulmonary drug delivery systems.
Fig. 11 Amounts of albuterol sulphate drug (AS) (%, nominal dose)
deposited on inhaler with mouthpiece adaptor (I+M) and throat (induction
port, IP) (mean±SD, n=4) (a); amounts of AS deposited on I+M or IP in
relation to charge density (mean±SD, n=6) (b) and Carr’s index (mean
±SD, n=5) (c) of spray dried mannitol (SDM) obtained from formulations
containing AS blended with SDM particles with different size fractions: 90–
125 μm (SDM–A), 63–90 μm (SDM–B), 45–63 μm (SDM–C) and 20–
45 μm (SDM–D). SDM powders with higher charge density and poorer
flowability deposited higher amounts of AS drug on I+M and IP.
Fig. 12 Overall desirability (DF) (mean±SD, n=4) for formulations con-
taining albuterol sulphate blended with spray dried mannitol (SDM) particles
with different size fractions: 90–125 μm (SDM–A), 63–90 μm (SDM–B),
45–63 μm (SDM–C) and 20–45 μm (SDM–D) and DF in relation to mean
diameter (mean±SD, n=10) of SDM. The overall desirability of the DPI
formulations increases with increasing particle size of SDM.
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However, it must be kept in mind that data provided in
the present study were restricted to one model of an inhaler
device and one model of drug. A different inhaler device or
drug (e.g., more cohesive drug) might generate different
formulation performances.
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